Skip to content
Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics

ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics

  • Post published:November 22, 2025
  • Post category:Analysis/News/Pα+
Read more about the article AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

  • Post published:November 10, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

  • Post published:November 4, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Q3’25 Psychedelic Lobbying Update

Q3’25 Psychedelic Lobbying Update

  • Post published:October 29, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Q3’25 Investor Survey: What are Investors Most Concerned About?

Q3’25 Investor Survey: What are Investors Most Concerned About?

  • Post published:October 23, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Q3’25 Survey: What are Psychedelics Investors Excited About?

Q3’25 Survey: What are Psychedelics Investors Excited About?

  • Post published:October 21, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Psychedelic Funding Update: Q3 2025

Psychedelic Funding Update: Q3 2025

  • Post published:October 16, 2025
  • Post category:Analysis/Pα+
Read more about the article Q2 2025: Oregon Psilocybin Services Update

Q2 2025: Oregon Psilocybin Services Update

  • Post published:October 10, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Psychedelic Investor Survey Q3 2025

Psychedelic Investor Survey Q3 2025

  • Post published:October 7, 2025
  • Post category:Analysis/News
Read more about the article Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

  • Post published:September 22, 2025
  • Post category:Analysis/News/Pα+

End of content

No more pages to load

Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More